Stocks / Pharmaceuticals
NTLAPharmaceuticals
Intellia Therapeutics, Inc
$12.431d +7.4%5d +4.5%settled close · 2026-09-17
Mkt cap $1.5B (3/25)β 2.2452w $10.73–17.88Shares 118.1MInd. In Vitro & In Vivo Diagnostic SubstancesNasdaq since 2016Emp. 377HQ Cambridge, MAintelliatx.com
The tape, with the calls on it
Who said what, and what NTLA did next
Every dot is a day someone on the record made a call. Hover one to see who. We are not scoring them — the point is that you can see it and judge for yourself.
bullish
bearish
both sides
Who’s talkingIdea Scout · free
Who’s talking about NTLA
1 longlatest 2026-01-23
| Date | Voice | Stance | Venue | Thesis |
|---|---|---|---|---|
| 2026-01-23 | Cathie WoodCEO & CIO, ARK Invest | Bullish | ARK Invest | Intellia's in vivo CRISPR gene editing trial for HAE offers a one-time cure worth up to $11M in system… |
Idea Scout tracks who’s
talking across television, podcasts, and interviews — every stance
dated to the appearance it came from.
Sign up free →
Earnings
Next report: 4 Nov 2026
Confirmed date · consensus EPS -0.82. Reactions below are the next settled session over the prior close.
The options tapeThe Brief · paid
Notable options days
Sessions in the last 120 where NTLA’s settled options volume ran ≥ 2× its trailing 20-session baseline, or delta-dollar flow ran ≥ 2.5× — 8 of 120 sessions qualified.
The qualifying dates are the free record. Close, flow, call/LEAPS mix and the 20-session outcome — for every session below — are Brief subscriber content.
| Date | Close | RVOL | Δ$ flow ($M) | Call % | LEAPS % | +20 sess. |
|---|---|---|---|---|---|---|
| 2026-09-17 | ||||||
| 2026-08-25 | ||||||
| 2026-08-19 | ||||||
| 2026-08-18 | ||||||
| 2026-07-16 | ||||||
| 2026-06-17 | ||||||
| 2026-06-16 | ||||||
| 2026-06-15 |
+20 sess. = raw price change over the following 20
sessions — not market-adjusted; the tape tells you where to look,
not what happens next.
Today’s tape on
NTLA is in this morning’s Brief.
Get The Brief — $20/mo →